Figure S3.

Mortality Analysis of Flies Exposed to 15.6 μM Trametinib, Related to Figure 5

(A) Combined survival data from three independent trials of wDah females exposed to 15.6 μM trametinib. Log-rank detected a significant difference in survival between trametinib-treated flies and untreated controls (increase in median lifespan of 9%, p < 0.0001). Controls: n = 338 deaths/8 censors, median lifespan = 75 days; trametinib-treated: n = 325/28, median lifespan = 82 days.

(B) Age-specific mortality analysis of the survival data in (A). Mortality (μx) was calculated as: μx = -ln(1-qx), where qx (the probability of dying in a time interval) was averaged per day over a 5-day interval and is shown at the end of the interval. Intervals with zero deaths were removed. Estimates of the parameters of the Gompertz mortality model: λ (baseline mortality) controls = 7.3x10⁻⁶, trametinib-treated = 2.3x10⁻⁶, p = 0.045; γ (change in mortality with age) controls = 0.13, trametinib-treated = 0.13, p = 0.67.